Panel Consolidates Pradaxa Bleeding Lawsuits to Central Federal Court

Share Article

The Pradaxa Resource Center is the Web’s largest source for information on Pradaxa research, side effects and legal news. Visit http://www.Pradaxa-lawsuits.org

Pradaxa lawsuit
Anyone who has suffered internal bleeding or had a loved one affected by taking Pradaxa is encouraged to speak with a lawyer about their legal rights as soon as possible.

The Pradaxa Resource Center, a patient advocacy group, is alerting patients who have suffered internal bleeding after taking the drug Pradaxa that a federal panel recently consolidated all lawsuits to one central court, which will expedite litigation for victims.

Anyone who has suffered internal bleeding or had a loved one affected by taking Pradaxa is encouraged to speak with a lawyer about their legal rights as soon as possible.

Pradaxa is a popular blood thinning drug prescribed to prevent strokes and blood clots in patients with atrial fibrillation. Although only on the market since October, 2010, Pradaxa has sold over $1 billion in the year ending February, 2012, according to a Wall Street Journal report on April 24, 2012.

On December 7, 2011, however, the FDA warned hundreds of thousands of patients that it was investigating the safety of Pradaxa after receiving more injury or death reports from the drug than expected. The Institute for Safe Medication Practices also reported on June 6, 2012 that Pradaxa led all other medications in 2011 for reports to the FDA of death or bleeding.

Due to the number of lawsuits expected over Pradaxa bleeding injury or death, lawyers filed a motion on May 30, 2012 requesting that all cases be moved to one central federal court. The case is known as MDL No. 2385 IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. In the motion, lawyers state they expect as many as 500 Pradaxa lawsuits will be filed.

After hearing arguments from lawyers involved in the litigation, the United States Judicial Panel on Multidistrict Litigation (JPML) issued an order on August 8, 2012 consolidating Pradaxa lawsuits to the Southern District of Ilinois, under Judge David Herndon.

The panel noted that Judge Herndon is highly qualified in large-scale drug injury matters, most recently Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100).

The Pradaxa Resource Center believes moving all Pradaxa lawsuits into one federal court will expedite the litigation process and help victims share in valuable evidence. However, due to the specialized nature of these federal MDL cases, victims should make sure any lawyer they choose has experience in this type of litigation.

Those affected by a Pradaxa injury are urged to speak with a lawyer about their legal options and find out if a Pradaxa lawsuit is possible. The Pradaxa Resource center works only with lawyers who are already handling Pradaxa lawsuits.

For more information on the research, warnings, side effects and legal options relating to the drug Pradaxa, or to speak with a lawyer, visit http://www.Pradaxa-lawsuits.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Schroeder
Visit website